FY2019 · ended Dec 31, 2019 · Revenue $0 · Filed Mar 4, 2021
Larimar Therapeutics, Inc. (LRMR) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$113.3 million. As of Jun 30, 2026 it held $156.3 million in cash and investments and $5.0 million in total debt.
Revenue (TTM)
$0
Net income (TTM)
$-25.08M
+50.0% vs year-ago TTM
Operating cash flow (TTM)
$-155.92M
-69.0% vs year-ago TTM
Free cash flow (TTM)
$-156.08M
-68.6% vs year-ago TTM
EPS
$-1.32
-57.1% vs prior year
Dividend per share
None
Shares outstanding
103.88M
+62.2% vs prior year
Net cash
$151.31M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LRMR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bala Cynwyd, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1374690
- Former names
- ZAFGEN, INC. (until May 19, 2020); ZAFGEN INC (until Nov 3, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$172.5M | -$90.9M | -$41.8M | -$36.5M | -$50.5M |
| Net income | -$165.7M | -$80.6M | -$36.9M | -$35.4M | -$50.6M |
| Diluted EPS | — | -$1.32 | -$0.84 | -$1.37 | -$2.95 |
| Operating cash flow | -$113.2M | -$70.8M | -$33.5M | -$27.6M | -$42.1M |
| Free cash flow | -$113.3M | -$71.3M | -$33.6M | -$27.7M | -$42.4M |
| Total assets | $145.8M | $200.2M | $95.9M | $126.4M | $78.7M |
| Total liabilities | $67.8M | $28.4M | $14.2M | $15.5M | $14.3M |
| Stockholders' equity | $78.1M | $171.8M | $81.7M | $110.9M | $64.4M |
| Cash and investments | $136.9M | $183.5M | $86.8M | $118.4M | $70.1M |
| Total debt | $4.1M | $5.1M | $5.5M | $5.4M | $6.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 29, 2026 | Sep 29, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Other events
|
Jun 29, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 19, 2026 | May 19, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
All 696 Larimar Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.